Literature DB >> 29446233

Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness.

Melissa A Rolfes1, Ivo M Foppa1,2, Shikha Garg1, Brendan Flannery1, Lynnette Brammer1, James A Singleton3, Erin Burns1, Daniel Jernigan1, Sonja J Olsen1, Joseph Bresee1, Carrie Reed1.   

Abstract

BACKGROUND: Estimates of influenza disease burden are broadly useful for public health, helping national and local authorities monitor epidemiologic trends, plan and allocate resources, and promote influenza vaccination. Historically, estimates of the burden of seasonal influenza in the United States, focused mainly on influenza-related mortality and hospitalization, were generated every few years. Since the 2010-2011 influenza season, annual US influenza burden estimates have been generated and expanded to include estimates of influenza-related outpatient medical visits and symptomatic illness in the community.
METHODS: We used routinely collected surveillance data, outbreak field investigations, and proportions of people seeking health care from survey results to estimate the number of illnesses, medical visits, hospitalizations, and deaths due to influenza during six influenza seasons (2010-2011 through 2015-2016).
RESULTS: We estimate that the number of influenza-related illnesses that have occurred during influenza season has ranged from 9.2 million to 35.6 million, including 140 000 to 710 000 influenza-related hospitalizations. DISCUSSION: These annual efforts have strengthened public health communications products and supported timely assessment of the impact of vaccination through estimates of illness and hospitalizations averted. Additionally, annual estimates of influenza burden have highlighted areas where disease surveillance needs improvement to better support public health decision making for seasonal influenza epidemics as well as future pandemics. Published 2018. This article is a U.S. Government work and is in the public domain in the USA. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.

Entities:  

Keywords:  United States; burden; influenza

Mesh:

Substances:

Year:  2018        PMID: 29446233      PMCID: PMC5818346          DOI: 10.1111/irv.12486

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN: 1750-2640            Impact factor:   4.380


INTRODUCTION

Estimates of the burden of seasonal influenza are broadly useful for public health, helping national and local authorities monitor epidemiologic trends, plan and allocate resources, demonstrate the impact of vaccine programs as well as other public health and clinical interventions, and inform the public, clinicians, and policymakers about the importance of influenza and influenza prevention. Estimates of the burden of seasonal influenza in the United States have evolved over time. First, estimates focused on the number of deaths due to influenza in the 1960s.1 With better access to hospital records, estimates were expanded to include influenza‐related hospitalizations.2, 3 During the 2009 H1N1 pandemic, there was a need to describe the burden of less severe outcomes, which further expanded the burden estimation to include outpatient medical visits and illness in the community.4 Changes were also made to the methods used to generate estimate of influenza burden. Statistical models were initially used to estimate excess deaths and hospitalizations, those that occur above what is predicted based on historical trends.1, 5, 6 During the 2009 H1N1 pandemic, there was a move toward using a multiplier that could extrapolate rates of hospitalization to rates of less severe disease. Historically, new estimates of influenza‐related mortality or hospitalization over multiple influenza seasons were published periodically, as new data became available.5, 6, 7 However, a hallmark of influenza is its variability from one season to the next and periodic assessments of the burden of influenza fail to capture the full extent of seasonal variation. For this reason, the Centers for Disease Control and Prevention (CDC) has transitioned from providing periodic estimates to reporting annual estimates of influenza burden in the United States. Annual estimates of disease burden, in combination with annual assessments of influenza vaccine coverage and vaccine effectiveness in preventing disease, allow for timely evaluation of influenza prevention and control efforts.

GENERATING ANNUAL ESTIMATES OF INFLUENZA BURDEN

Data from the 2010‐2011 through 2015‐2016 influenza seasons (October through April) have been used on an annual basis to estimate the burden of seasonal influenza and the disease burden averted by influenza vaccination in the United States.8, 9, 10, 11, 12, 13 The methods have previously been described in detail (Fig. S1).7, 9, 11, 12, 13, 14 Briefly, rates of hospitalization with laboratory‐confirmed influenza were obtained from the Influenza Hospitalization Surveillance Network (FluSurv‐NET), a population‐based surveillance conducted in 14 geographically distributed states.15 Hospitalization rates were generated by age group (0‐4, 5‐17, 18‐49, 50‐64, and ≥65 years). Rates were adjusted for influenza testing practices and test sensitivity and then applied to the US population to obtain estimates of the number of influenzaassociated hospitalizations that occurred each season. Estimates of excess deaths related to influenza were based on a statistical model of the weekly number of deaths obtained from the National Center for Health Statistics.16 The model accounts for seasonal trends in mortality and weekly circulation of influenza and respiratory syncytial virus, obtained from national virologic surveillance.16, 17 The model was fitted using Markov chain Monte Carlo methods, yielding “point estimates” (mean or median of the empirical posterior distribution) and “confidence intervals” (95% credible intervals) for the number of deaths attributable to influenza. Data on deaths with pneumonia or influenza listed as a cause of death were used in the statistical model because they are available in near real time. However, most influenza‐related deaths are likely not due directly to influenza virus infection but may be due to secondary bacterial infection or worsening of underlying chronic health conditions, such as chronic heart or lung disease. Even when influenza likely contributed to the events leading to a death, it may not be recognized and is rarely listed on the death certificate. From prior analyses, the number of deaths associated with influenza may be two to four times higher than the number of deaths related to influenza that have pneumonia or influenza listed on the death certificate.7, 18 Deaths with any respiratory or circulatory causes listed on the death certificate are likely more inclusive of deaths related to influenza than deaths with pneumonia or influenza causes; therefore, additional statistical models were created using death from respiratory or circulatory causes. Data on respiratory and circulatory deaths were available with a 3 year lag; therefore, in 2016, data were available and summarized for the 2010‐2011 season through the 2013‐2014 season only. Estimates of the case‐to‐hospitalization ratio, obtained from studies during the 2009 pandemic in the United States,4 were used to calculate the number of illness episodes that occurred in the community from the number of hospitalizations with laboratory‐confirmed influenza. Estimates of the proportion of ill persons who sought medical care, obtained from a nationwide behavior survey conducted in the United States during the 2009 pandemic,19 were used to estimate the number of outpatient medical visits relative to the estimated number of influenza illnesses in the community. Estimates of the numbers of influenzaassociated illnesses, outpatient medical visits, hospitalizations, and deaths prevented by influenza vaccination were derived from burden estimates, influenza vaccination coverage, and vaccine effectiveness, as previously described.9 Briefly, estimates of monthly influenza vaccine coverage by age group (6 months‐4 years, 5‐17, 18‐49, 50‐64, and ≥65 years) and annual vaccine effectiveness estimates were used to estimate the number of influenza outcomes that would have occurred in the absence of vaccination, assuming equal vaccine effectiveness against each outcome.20, 21 From the estimates of burden estimates, vaccination coverage, and vaccine effectiveness, we calculated age group‐specific hypothetical numbers of illness, medical visits, hospitalizations, and respiratory or circulatory deaths related to influenza per month that would have occurred in the absence of vaccination (assuming only a direct vaccination effect). The outcomes prevented by vaccination were the difference between these hypothetical numbers and the burden estimates for the actual population. The fraction of hospitalizations prevented by vaccination was the total number of hospitalizations averted divided by the number of hospitalizations that would have occurred in the absence of vaccination. The model of averted outcomes was also used to estimate the incremental benefits expected from increasing vaccine coverage or vaccine effectiveness. The number needed to vaccinate to prevent one influenzaassociated illness was estimated by dividing the size of the vaccinated population in the United States by the number of illnesses prevented by vaccination. Estimates of the number of illnesses, outpatient medical visits, hospitalizations, and respiratory and circulatory deaths related to seasonal influenza in the United States and the number of illnesses, medical visits, hospitalizations, and deaths related to influenza that were prevented by influenza vaccination are updated annually and published online.13

ESTIMATED BURDEN OF INFLUENZA‐ASSOCIATED ILLNESS, OUTPATIENT MEDICAL VISITS, HOSPITALIZATIONS, AND DEATHS

Over the past six influenza seasons in the United States (2010‐2011 through 2015‐2016), we estimate that influenzaassociated illnesses have ranged from a low of 9.2 million to a high of 35.6 million illnesses, with variation by age (Table 1). Outpatient medical visits related to influenza have ranged from 4.3 million to 16.7 million, while influenzaassociated hospitalizations have ranged from 139 000 to 708 000. From 2010‐2011 through 2013‐2014 influenza seasons, influenzaassociated respiratory and circulatory deaths have ranged from a low of 12 000 to a high of 56 000, and associated pneumonia and influenza deaths have ranged from 4000 to 12 000 over the six seasons from 2010‐2011 through 2015‐2016. Figure 1 is a visual representation of the burden of influenza, which depicts the relative magnitude of each season's burden in the United States.
Table 1

Six‐season range of symptomatic community illnesses, outpatient medical visits, hospitalizations, and excess deaths related to influenza, by age group—United States, 2010‐2011 through 2015‐2016 influenza seasons

Age groupSymptomatic community illnessOutpatient medical visitsHospitalizationsExcess deaths
Pneumonia & influenzaa Respiratory & circulatoryb
Overall9 200 000–35 600 0004 200 000–16 700 000139 000–708 0004000–20 00012 000–56 000
<5 y900 000–3 800 000600 000–2 500 0006000–26 00060–300100–700
5–17 y1 900 000–6 900 0001 000 000–3 600 0005000–19 00050–300100–600
18–49 y3 400 000–12 600 0001 200 000–4 700 00019 000–71 000300–2100900–3600
50–64 y1 800 000–8 800 000800 000–3 800 00020 000–93 000600–34001800–7500
≥65 y900 000–5 800 000500 000–3 300 00087 000–523 0003000–17 0009000–43 000

Only data on pneumonia and influenza deaths were available in real time during an influenza season; however, pneumonia and influenza deaths are only a subset of the total deaths associated with influenza that occur each year, which may be 2 to 4 times higher when other complications are also considered.

Data on respiratory and circulatory deaths are available with a three‐year lag; therefore, estimates of excess respiratory and circulatory deaths are only available through 2013‐2014 influenza season at this time.

Figure 1

Relative number of community illnesses, outpatient medical visits, hospitalizations, and deaths associated with seasonal influenza—United States, 2010‐2011 through 2015‐2016 influenza seasons. *Only data on pneumonia and influenza deaths were available in real time during an influenza season; however, pneumonia and influenza deaths are only a subset of the total deaths associated with influenza that occur each year, which may be 2 to 4 times higher when other complications are also considered

Six‐season range of symptomatic community illnesses, outpatient medical visits, hospitalizations, and excess deaths related to influenza, by age group—United States, 2010‐2011 through 2015‐2016 influenza seasons Only data on pneumonia and influenza deaths were available in real time during an influenza season; however, pneumonia and influenza deaths are only a subset of the total deaths associated with influenza that occur each year, which may be 2 to 4 times higher when other complications are also considered. Data on respiratory and circulatory deaths are available with a three‐year lag; therefore, estimates of excess respiratory and circulatory deaths are only available through 2013‐2014 influenza season at this time. Relative number of community illnesses, outpatient medical visits, hospitalizations, and deaths associated with seasonal influenza—United States, 2010‐2011 through 2015‐2016 influenza seasons. *Only data on pneumonia and influenza deaths were available in real time during an influenza season; however, pneumonia and influenza deaths are only a subset of the total deaths associated with influenza that occur each year, which may be 2 to 4 times higher when other complications are also considered

ESTIMATED INFLUENZA‐ASSOCIATED DISEASE BURDEN PREVENTED THROUGH INFLUENZA VACCINATION

Given the estimates of seasonal incidence of influenza, the associated burden of severe disease, and estimates of influenza vaccine effectiveness and coverage in the United States, we estimate that influenza vaccination has prevented between 1.6 million and 6.7 million illnesses, 790 000‐3.1 million outpatient medical visits, 39 000‐87 000 hospitalizations, and 3000‐10 000 respiratory and circulatory deaths related to influenza each season (Table 2).
Table 2

Estimated number and fraction of influenza illnesses, medical visits, hospitalizations, and pneumonia and influenza deaths averted by vaccination, by season—United States, 2010‐2011 through 2015‐2016 influenza seasons13

SeasonAverted illnessesAverted medical visitsAverted hospitalizationsAverted deaths
Pneumonia and influenza deathsa Respiratory and circulatory deathsb
No.95% CINo.95% CINo.95% CIFraction prevented (%)c No.95% CINo.95% CI
2010–20115 039 2773 435 322–7 716 9212 514 3531 702 599–3 885 77970 82133 965–141 70820.834341422–690698803883–19 362
2011–20121 981 5711 160 279–3 666 130968 312555 687–1 809 75339 30117 610–88 88522.71227505–245036181400–6909
2012–20135 628 3324 235 767–8 327 0822 701 8751 997 056–4 085 45261 52231 580–162 83611.11823724–551752802149–15 029
2013–20146 683 9295 037 991–8 898 3093 080 2842 252 594–4 190 94886 73056 447–129 73621.538402298–584491725267–14 465
2014–20151 606 813609 744–3 456 741792 958296 449–1 744 00147 44910 795–144 2917.51419312–4255
2015–20165 083 4983 538 000–7 081 3442 504 3231 725 971–3 532 83571 47942 344–112 22818.928821588–4562

Only data on pneumonia and influenza deaths were available in real time during an influenza season; however, pneumonia and influenza deaths are only a subset of the total deaths associated with influenza that occur each year, which may be 2 to 4 times higher when other complications are also considered.

Data on respiratory and circulatory deaths are available with a three‐year lag; therefore, estimates on averted respiratory and circulatory deaths are only available through 2013‐2014 influenza season at this time.

The estimated fraction of influenza‐associated hospitalizations prevented by vaccination was estimated by dividing the estimated number of averted hospitalizations by the estimated number of observed hospitalizations in a given season. Because the estimated number of illnesses in the community and outpatient medical visits is proportional to the estimated hospitalizations, the estimated fraction of community illnesses and outpatient medical visits prevented by vaccination is identical to the fraction of hospitalizations prevented by vaccination.

Estimated number and fraction of influenza illnesses, medical visits, hospitalizations, and pneumonia and influenza deaths averted by vaccination, by season—United States, 2010‐2011 through 2015‐2016 influenza seasons13 Only data on pneumonia and influenza deaths were available in real time during an influenza season; however, pneumonia and influenza deaths are only a subset of the total deaths associated with influenza that occur each year, which may be 2 to 4 times higher when other complications are also considered. Data on respiratory and circulatory deaths are available with a three‐year lag; therefore, estimates on averted respiratory and circulatory deaths are only available through 2013‐2014 influenza season at this time. The estimated fraction of influenzaassociated hospitalizations prevented by vaccination was estimated by dividing the estimated number of averted hospitalizations by the estimated number of observed hospitalizations in a given season. Because the estimated number of illnesses in the community and outpatient medical visits is proportional to the estimated hospitalizations, the estimated fraction of community illnesses and outpatient medical visits prevented by vaccination is identical to the fraction of hospitalizations prevented by vaccination. Surveys in the US population suggest that overall vaccination coverage was 42%‐47% over the past six influenza seasons, although coverage varies considerably by age.22 Increases in vaccination coverage can translate to large reductions in influenzaassociated disease burden when influenza viruses in the vaccine are similar to circulating viruses. For example, during the 2015‐2016 influenza season, overall vaccination coverage was 46% and we estimate that vaccination prevented more than 5 million illnesses and 71 000 hospitalizations. If vaccination coverage had been increased by five percentage points across all age groups, more than 500 000 additional illnesses and 6000 additional hospitalizations would have been prevented. The burden models can also serve to assess the impact of changes in vaccine effectiveness on an annual basis. For example, during the 2014‐2015 influenza season, the influenza A/H3N2 virus that circulated widely drifted, both genetically and antigenically, after vaccine virus recommendations were made, leading to reduced overall vaccine effectiveness (19%) against influenza A viruses.23 Given the reduced vaccine effectiveness and high burden of illness, we estimated that, on average, 92 people needed to be vaccinated to prevent a single case of influenza and 3115 people needed to be vaccinated to prevent a single hospitalization. Changes in the vaccine composition and improved vaccine effectiveness (47%) against the circulating influenza virus types during the 2015‐2016 season, along with fewer hospitalized patients, meant that only 29 people needed to be vaccinated, on average, to prevent a single case of influenza and 2033 needed to be vaccinated to prevent one influenzaassociated hospitalization.21, 24

DISCUSSION

Periodic estimates of the burden of seasonal influenza in the United States have been made for more than 50 years, focused mainly on mortality and hospitalization related to influenza. In response to the 2009 pandemic and the need for timely data on burden and severity, CDC now generates annual burden estimates and has also expanded burden estimates to include less severe outcomes. These estimates have allowed for timely communication about the importance of vaccination to prevent influenza and helped frame discussions about influenza program goals with policymakers. Annual estimates have reinforced the message that influenza is ever‐changing and will likely differ from one season to the next and we use a range to describe burden in order to more accurately reflect the annual variability of influenza. In addition to being reported annually, CDC estimates of influenza disease burden were expanded to include outpatient medical visits and symptomatic community illness. Estimates focused on influenza‐related mortality and hospitalizations reinforce the potentially serious nature of influenza, but are a small fraction of the total burden of influenza and can be biased, as they are highly influenced by patterns and policies for hospital admission, influenza testing, and reporting.11 On the other hand, estimates of the number of symptomatic community illnesses, for which medical care is not sought but may still result in missed school or work, and outpatient medical visits due to influenza underscore the frequency of influenza illness and its widespread societal impact. We estimate that for every influenza‐related hospitalization, between 11 and 365 more non‐hospitalized cases occur in the community, depending on the age group.4, 8 Generating annual estimates of influenza burden helped CDC recognize gaps in influenza surveillance activities. For example, there were no means to directly estimate medically‐attended and community illness during the 2009 pandemic. Instead, these portions of influenza burden were indirectly estimated using the rates of influenzaassociated hospitalization and field‐validated multipliers of healthcare utilization and case‐to‐hospitalization ratios from the 2009 H1N1 pandemic. In an effort to fill these gaps, there are now several ongoing efforts and collaborations to gather data that can directly estimate the burden of medically‐attended illness related to influenza as well as symptomatic community illness on a routine basis.25, 26, 27 Not only are these improvements to surveillance helpful during seasonal epidemics, but the creation and optimization of surveillance activities that are routine, robust, and near real time will be helpful when a pandemic occurs.16, 28 The methods and estimates of seasonal influenza burden are not without limitations. First, influenza vaccination coverage estimates and the multipliers used for estimating outpatient medical visits and symptomatic community illness were derived from survey respondents and are subject to recall bias and non‐response bias. Second, the model of disease prevented through vaccination only calculated outcomes averted through direct protection of persons who were vaccinated, and not indirect or herd protection. Third, this same model assumed a single estimate of vaccine effectiveness against all outcomes and constant effectiveness over the course of the season within each age group, which may be oversimplifications. Fourth, estimates of influenzaassociated mortality were based on an ecologic analysis at the national level and may wrongly attribute mortality above an imputed “baseline” to influenza. In addition, it may not reflect the burden on a different level, such as the state or local level. Despite their limitations, the models we use for estimating the burden of seasonal influenza are simple and provide timely information that is valuable for public health activities. Burden estimates are invaluable for estimating the economic and societal costs of influenza and making decisions about procurement of vaccines and influenza antivirals before the influenza season begins. At CDC, we have also found that providing estimates of burden on an annual basis has served to strengthen existing influenza surveillance activities, allowed for timely communication of the value of vaccination, improved our understanding of the epidemiology of seasonal influenza in the United States, and enhanced preparedness for future influenza pandemics. Click here for additional data file.
  20 in total

1.  Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons.

Authors:  Michael L Jackson; Lisa A Jackson; Burney Kieke; David McClure; Manjusha Gaglani; Kempapura Murthy; Ryan Malosh; Arnold Monto; Richard K Zimmerman; Ivo M Foppa; Brendan Flannery; Mark G Thompson
Journal:  Vaccine       Date:  2015-08-11       Impact factor: 3.641

2.  Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.

Authors:  Hong Zhou; William W Thompson; Cecile G Viboud; Corinne M Ringholz; Po-Yung Cheng; Claudia Steiner; Glen R Abedi; Larry J Anderson; Lynnette Brammer; David K Shay
Journal:  Clin Infect Dis       Date:  2012-04-10       Impact factor: 9.079

3.  Estimates of deaths associated with seasonal influenza --- United States, 1976-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-08-27       Impact factor: 17.586

4.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

5.  Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13.

Authors:  Ashley Fowlkes; Andrea Steffens; Jon Temte; Steve Di Lonardo; Lisa McHugh; Karen Martin; Heather Rubino; Michelle Feist; Carol Davis; Christine Selzer; Jose Lojo; Oluwakemi Oni; Katie Kurkjian; Ann Thomas; Rachelle Boulton; Nicole Bryan; Ruth Lynfield; Matthew Biggerstaff; Lyn Finelli
Journal:  Lancet Respir Med       Date:  2015-08-21       Impact factor: 30.700

6.  Influenza-associated hospitalizations in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

7.  2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type.

Authors:  Richard K Zimmerman; Mary Patricia Nowalk; Jessie Chung; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Arnold S Monto; Huong Q McLean; Edward A Belongia; Manjusha Gaglani; Kempapura Murthy; Alicia M Fry; Brendan Flannery
Journal:  Clin Infect Dis       Date:  2016-10-04       Impact factor: 20.999

8.  Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011.

Authors:  Deliana Kostova; Carrie Reed; Lyn Finelli; Po-Yung Cheng; Paul M Gargiullo; David K Shay; James A Singleton; Martin I Meltzer; Peng-Jun Lu; Joseph S Bresee
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

9.  Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season.

Authors:  Carrie Reed; Inkyu Kevin Kim; James A Singleton; Sandra S Chaves; Brendan Flannery; Lyn Finelli; Alicia Fry; Erin Burns; Paul Gargiullo; Daniel Jernigan; Nancy Cox; Joseph Bresee
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-12-12       Impact factor: 17.586

10.  The US Influenza Hospitalization Surveillance Network.

Authors:  Sandra S Chaves; Ruth Lynfield; Mary Lou Lindegren; Joseph Bresee; Lyn Finelli
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

View more
  109 in total

1.  Vaccination of Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic.

Authors:  Sheena Crosby; Michael J Schuh; Freddy Caldera; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-01

2.  Dynamic Perspectives on the Search for a Universal Influenza Vaccine.

Authors:  Chadi M Saad-Roy; Adrian B McDermott; Bryan T Grenfell
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

3.  Factors associated with parental acceptance of influenza vaccination for their children: the evidence from four cities of China.

Authors:  Mingyi Zhao; Haiyan Liu; Shujuan Qu; Li He; Kathryn S Campy
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

4.  Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors:  Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

5.  Racial/Ethnic Disparities in Influenza Vaccination Coverage Among US Adolescents, 2010-2016.

Authors:  Noah S Webb; Benjamin Dowd-Arrow; Miles G Taylor; Amy M Burdette
Journal:  Public Health Rep       Date:  2018-10-09       Impact factor: 2.792

6.  Increasing Protection of Dialysis Patients against Influenza.

Authors:  Megan C Lindley; David K Kim
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-23       Impact factor: 8.237

7.  Influenza Infection has Fiber Type-Specific Effects on Cellular and Molecular Skeletal Muscle Function in Aged Mice.

Authors:  Chad R Straight; Olivia R Ringham; Jenna M Bartley; Spencer R Keilich; George A Kuchel; Laura Haynes; Mark S Miller
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-11-13       Impact factor: 6.053

8.  Outcomes of Immunocompromised Adults Hospitalized With Laboratory-confirmed Influenza in the United States, 2011-2015.

Authors:  Jennifer P Collins; Angela P Campbell; Kyle Openo; Monica M Farley; Charisse Nitura Cummings; Mary Hill; William Schaffner; Mary Lou Lindegren; Ann Thomas; Laurie Billing; Nancy Bennett; Nancy Spina; Marisa Bargsten; Ruth Lynfield; Seth Eckel; Patricia Ryan; Kimberly Yousey-Hindes; Rachel Herlihy; Pam Daily Kirley; Shikha Garg; Evan J Anderson
Journal:  Clin Infect Dis       Date:  2020-05-06       Impact factor: 9.079

9.  Incidence of Hospitalization for Vaccine-Preventable Infections in Children Following Solid Organ Transplant and Associated Morbidity, Mortality, and Costs.

Authors:  Amy G Feldman; Brenda L Beaty; Donna Curtis; Elizabeth Juarez-Colunga; Allison Kempe
Journal:  JAMA Pediatr       Date:  2019-03-01       Impact factor: 16.193

10.  Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults : A Cross-sectional Study.

Authors:  Eric J Chow; Melissa A Rolfes; Alissa O'Halloran; Evan J Anderson; Nancy M Bennett; Laurie Billing; Shua Chai; Elizabeth Dufort; Rachel Herlihy; Sue Kim; Ruth Lynfield; Chelsea McMullen; Maya L Monroe; William Schaffner; Melanie Spencer; H Keipp Talbot; Ann Thomas; Kimberly Yousey-Hindes; Carrie Reed; Shikha Garg
Journal:  Ann Intern Med       Date:  2020-08-25       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.